ReviewGut microbes2020
Vaccines against gastroenteritis, current progress and challenges.
Review in Gut microbes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Rotavirus vaccines in Africa and Norovirus genetic diversity in children aged 0 to 5 years old: a systematic review and meta-analysis : Rotavirus vaccines in Africa and Norovirus genetic diversity.BMC infectious diseases · 2024Pooled it
- Trial
- Clinical characteristics and outcomes of bacterial and viral gastrointestinal infection by pathogen: a large-scale observational study in United States.Journal of gastroenterology · 2026Article
- Article
- Global, regional, and national impact of epidemic disasters on health workforce equality between 1990 and 2019: An ecological and modeling study.PLoS medicine · 2026Article
- MecVax, an Epitope- and Structure-Based Broadly Protective Subunit Vaccine Against EnterotoxigenicMicroorganisms · 2025Review
- Hidden Circulation and Socio-Sanitary Vulnerability: Rotavirus A and Human Adenovirus Prevalence in Symptomatic and Asymptomatic Children in Central Brazil Post-COVID-19.Pathogens (Basel, Switzerland) · 2025Article
- The association between all-cause mortality with drinking habits and water sources: a nationwide longitudinal study on Chinese elderly.Journal of global health · 2025Article
- Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990-2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021.The Lancet. Infectious diseases · 2025Article
- The current state of pediatric gastroenterology in under-resourced nations.Annals of medicine and surgery (2012) · 2025Review
- Review
- Non-antibiotic therapies for multidrug-resistant gastrointestinal infections: an overview of the use of probiotics, natural compounds, and bacteriophages.Frontiers in antibiotics · 2025Review
- Biotechnological Interventions for the Production of Subunit Vaccines Against Group A Rotavirus.Cell biochemistry and function · 2024Review
- Screening and Immune Efficacy Evaluation of Antigens with Protection Against Feline Calicivirus.Vaccines · 2024Article
- Trivalent outer membrane vesicles-based combination vaccine candidate induces protective immunity against Campylobacter and invasive non-typhoidal Salmonella in adult mice.Medical microbiology and immunology · 2024Article
- A Multi-Pathogen Retrospective Study in Patients Hospitalized for Acute Gastroenteritis.Diseases (Basel, Switzerland) · 2024Article
- Recent development of oral vaccines (Review).Experimental and therapeutic medicine · 2024Review
- QcrC is a potential target for antibody therapy and vaccination to controlFrontiers in microbiology · 2024Article
- A broadly immunogenic polyvalentInfection and immunity · 2023Article
- A Polyvalent Adhesin-Toxoid Multiepitope-Fusion-Antigen-Induced Functional Antibodies against Five EnterotoxigenicMicroorganisms · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Enteric viral and bacterial infections continue to be a leading cause of mortality and morbidity in young children in low-income and middle-income countries, the elderly, and immunocompromised individuals. Vaccines are considered an effective and practical preventive approach against the predominantly fecal-to-oral transmitted gastroenteritis particularly in the resource-limited countries or regions where implementation of sanitation systems and supply of safe drinking water are not quickly achievable. While vaccines are available for a few enteric pathogens including rotavirus and cholera, there are no vaccines licensed for many other enteric viral and bacterial pathogens. Challenges in enteric vaccine development include immunological heterogeneity among pathogen strains or isolates, a lack of animal challenge models to evaluate vaccine candidacy, undefined host immune correlates to protection, and a low protective efficacy among young children in endemic regions. In this article, we briefly updated the progress and challenges in vaccines and vaccine development for the leading enteric viral and bacterial pathogens including rotavirus, human calicivirus,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.